Topiramate Tablet
Product Images NDC 70518-2517

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-2517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Topiramate 25 mg tablet label indicating a quantity of 30 tablets. The label shows the product name, strength, dosage form, and that it is prescription only (RX ONLY). It includes repackager information for RemedyRepack Inc. and manufacturer Cipla USA, Inc., Miami, FL. Storage directions and a QR code are also visible.*

FDA Label Image

Topiramate 25mg 70518 2517 01

Topiramate 25 mg tablet packaging label shows a quantity of 100 tablets. It is repackaged by RemedyRepack Inc. The label includes an NDC number 70518-2517-01, with manufacturing by Cipla USA, Inc. Directions indicate to see the package insert, and storage temperatures are specified. The label includes a QR code and standard medication storage warnings.*

FDA Label Image

Topiramate 25mg 70518 2517 02

Label for Topiramate 25 mg oral tablet, quantity of 1, repackaged by RemedyRepack Inc. The label includes a QR code, NDC number 70518-2517-02, and manufacturer information Cipla USA, Inc., Miami, FL. Directions reference a package insert with storage instructions between 20-25°C and allowable excursions. The label notes the product is RX only and warns to keep medication out of children's reach.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

Chemical structure of the active ingredient Topiramate, depicting its molecular arrangement with characteristic functional groups and stereochemistry.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

A line chart depicting cumulative rates for time to first seizure over time (days) for two dosages of Topiramate: 50 mg/day (solid line, N=234) and 400 mg/day (dotted line, N=236). The chart shows comparative seizure occurrence over a 500-day period, with a p-value of 0.0002 indicating statistical significance between the two groups.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

A bar graph showing the change from baseline to double-blind phase in average monthly migraine period days (± standard error) across two studies. The graph compares placebo and Topamax doses of 50 mg/day, 100 mg/day, and 200 mg/day, with higher doses associated with greater reductions. Statistical significance is indicated by asterisks for p-values less than 0.010 and 0.001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.